EBOS Group stock draws a Strong Buy consensus after FY2026 growth

Published on 10/07/2026 at 05:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EBOS Group stock had 8 analysts behind an average AUD 23.81 target on October 5, 2026. FY2026 revenue rose 9.9 percent to AUD 13.5 billion.

EBO, NZEBOE0001S6, Illustration mit AI erstellt.

EBOS Group (ISIN NZEBOE0001S6) was trading at NZD 18.95 on the NZX on October 7, 2026 at 3:57 p.m. NZDT, down 0.99 percent from the prior close of NZD 19.14. The latest analyst snapshot gives the stock a Strong Buy consensus, with an average AUD 23.81 target from eight analysts, according to The Globe and Mail on October 5, 2026.

FY2026 revenue rose 9.9 percent

EBOS delivered its latest full-year result for the period ended June 30, 2026. According to Yahoo Finance on August 19, 2026, revenue increased 9.9 percent to AUD 13.5 billion, while underlying EBITDA rose 5 percent to AUD 614 million. Underlying NPAT was AUD 250 million, and statutory NPAT increased 4.7 percent.

The result shows a company growing through scale rather than a single product line. Healthcare revenue reached AUD 12.6 billion, up 8.5 percent, while Animal Care revenue increased 34.6 percent to AUD 907 million, with EBITDA of AUD 138 million.

Investment cycle shifts to productivity

Management said the AUD 360 million distribution center renewal program was complete in FY2026, with all facilities operating. The change matters financially because the group expects FY2027 capital expenditure to normalize at AUD 100 million, compared with AUD 145 million in FY2026, according to Yahoo Finance on August 19, 2026.

EBOS also finished FY2026 with leverage of 2.1 times and maintained its final dividend at NZD 0.615 per share. The company describes itself as an Australasian marketer, wholesaler and distributor of healthcare, medical, pharmaceutical and animal care products, according to its investor page.

EBOS Group stock remains below yearly high

At NZD 18.95 on October 7, 2026, the stock was 36.8 percent below its 52-week high of NZD 29.99 and above its 52-week low of NZD 18.45. The market capitalization was NZD 3.9 billion, with 91,795 shares traded at the quoted time.